Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

(RTTNews) - Johnson & Johnson (JNJ) Friday announced positive results from Phase 3b SPECTREM study of Tremfya to treat adults with low body surface area (BSA) moderate plaque psoriasis (PsO) in ...

Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...

Sensitive or highly visible areas affected by PsO, including the scalp, face, skin folds and genitals, are considered "special sites" and can have significant impact on patients' daily lives ...

These results were comparable irrespective of baseline BSA. Results Demonstrate High Levels of Skin Clearance in Patients with Special Site Involvement 2,3,4 Significant clearance (defined as ...

1 Day PSO -1.47% DJIA -0.36% S&P 500 0.16% Energy -0.57% ...